Press Releases
Site - Investor Relations
Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development
“Pamela’s track record of innovative and collaborative leadership positions fit perfectly as we begin to commercialize our technologies,” said
“Predictive Oncology has focused on bringing together multiple novel technologies and research approaches to predict treatment outcomes for drug formulations in cancer patients,” Bush said. “I’m looking forward to bringing these capabilities to the market as soon as possible and working with our partners to make it the new gold standard of cancer research. The world has waited long enough for a targeted method devised to eliminate cancer.”
In addition to her sales role, Bush will work with the company’s senior leadership team to identify opportunities for business development, including additional acquisitions and licensing agreements. She will also serve to further integrate POAI’s new acquisition of zPREDICTA into the company.
Before coming to
About
As the drug discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics.
Forward-Looking Statements: Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
(404) 995-6671
kpinder@landoncapital.net
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4b6a619d-1efa-4428-8509-cfd4a62e6127
Source: Predictive Oncology Inc.